跳至主要内容
临床试验/ACTRN12622000383763
ACTRN12622000383763已完成2 期

Systematic Evaluation of Interventions for Symptom Management In Chronic Kidney Disease – CannaBiDiol (SEISMIC-CBD)

niversity of Sydney0 个研究点目标入组 12 人开始时间: 2022年3月4日最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1.Adults greater than or equal to 18 years with kidney failure as defined by:
  • a.eGFR less than or equal to 15ml/min/1.73m2 (measured by Chronic Kidney Disease-Epidemiology Collaboration [CKD-EPI] equation) on at least two blood tests within the past three (3) months
  • b.receiving maintenance dialysis (haemodialysis or peritoneal dialysis),
  • 2.A score of greater than or equal to 4 on at least one of the following domains of ESASr-Renal: pain, nausea, lack of appetite, itching, problem sleeping, restless legs, tiredness, and
  • 3.Participant and treating clinician are willing to perform the study procedures.

排除标准

  • 1.Active on the kidney transplant waitlist
  • 2.Taking a disqualifying concomitant medication that cannot be ceased during the study period.
  • 3.Use of recreational or prescribed cannabis products in the past 4 weeks and unwilling to refrain from using such products for the duration of the present study.
  • 4.Unstable mood disorder. Defined as commencing therapy for depression or anxiety (pharmacotherapy or non-pharmacotherapy) within the past 3 months, or in the opinion of the investigator.
  • 5.Pregnant or breast-feeding
  • 6.Significant hepatic disease, defined as either of the following
  • a.Known or suspected cirrhosis (of any degree)
  • b.Elevated liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], or gamma-glutamyl transferase [GGT]) more than 2x the upper limit of normal on blood tests taken within 3 months of the date of screening.
  • 7.Unwilling or unable to follow study procedures
  • 8.Unwilling or unable to refrain from driving within 24 hours of receiving THC wafer.
  • 9.In the opinion of the treating investigator: death likely within three months
  • 10.Taking clopidogrel AND meeting at least ONE of the following conditions in the past (6) months:
  • a.Placement of a coronary artery stent
  • b.Acute myocardial infarction
  • c.Cerebrovascular accident

研究者

相似试验